Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-MS: AHSCT vs Best Available Therapy for Treatment-Resistant Relapsing MS
NCT04047628Phase 3Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2020
- Primary completion
- Aug 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous hematopoietic stem cells in multiple sclerosis (MS), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2020; status: recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04047628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047628.